Is Vilin Bio Med overvalued or undervalued?
As of September 16, 2025, Vilin Bio Med is considered very expensive and overvalued, with a PE Ratio of 35.99 and an EV to EBIT of 38.51, significantly higher than peers like Sun Pharma and Cipla, despite recent stock performance outpacing the Sensex.
As of 16 September 2025, the valuation grade for Vilin Bio Med has moved from expensive to very expensive. This indicates that the company is currently overvalued. The key ratios reveal a PE Ratio of 35.99, an EV to EBIT of 38.51, and a ROCE of only 2.66%, which are significantly higher than many peers in the industry. In comparison, Sun Pharma has a PE Ratio of 33.64 and an EV to EBIT of 22.76, while Cipla stands at a more attractive PE Ratio of 23.31 and an EV to EBIT of 16.42. These figures suggest that Vilin Bio Med's valuation is not justified when compared to its peers, indicating a potential overvaluation. Additionally, the company's recent stock performance has outpaced the Sensex over the past week, with a return of 10.02% compared to the Sensex's 1.49%, but this does not mitigate the overall valuation concerns.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
